# Ipamorelin: The Newest Research on a Selective GH Secretagogue > Ipamorelin is a selective growth hormone secretagogue, and the 2024-2026 studies are the freshest part of the story. A plain-English research digest, every claim cited. A fresh-research-first digest of what ipamorelin actually does, what the 2024-2026 papers found, and where the evidence still runs thin. Every number is cited. ## The short version Ipamorelin is a small lab-made peptide — five amino acids strung together — that tells your pituitary gland to release a pulse of growth hormone (GH). It does one thing very cleanly: it bumps GH without dragging up stress hormones like cortisol, which older peptides in its family always did [1]. That clean profile is its whole reputation. Here is the honest part. The freshest study, from 2024, is in ferrets — ipamorelin cut chemotherapy-driven weight loss by about a quarter [5]. Most of the rest is rats, plus one human safety-and-dose study [2] and one human trial for slow bowels after surgery that simply did not work [3]. It is **not** an FDA-approved drug, it is not prescribed, and despite the word in this site's name, no one can write you a prescription for it. People still use it off-label — and [what people report](/effects), including the downsides, is on its own page. This site just reads the science back to you in plain English. ## What the newest ipamorelin research is actually finding Lead with the fresh stuff, because that is the whole point of this site. In 2024, intraperitoneal ipamorelin (1-3 mg/kg) cut cisplatin-induced body-weight loss in ferrets by roughly 24% during the delayed phase of chemotherapy nausea — but it did nothing for the vomiting itself [5]. That is the most recent in-vivo ipamorelin study on record, and it points the research toward cachexia (disease-driven wasting), not toward the muscle-building story the internet tells. Also in 2024: a separate ghrelin-system paper showed that unacylated ghrelin protected aging muscle from losing mass and strength [7]. Ipamorelin was not the tested molecule, but it targets the same receptor family, so the finding frames why researchers keep circling ghrelin biology for sarcopenia (age-related muscle loss). And in a tilapia study, ipamorelin acetate raised reproductive hormones and pushed germ-cell development, hinting the ghrelin receptor talks to the reproductive axis too [13]. None of these are human efficacy trials — they are the frontier, not the finish line. ## Selectivity is the headline finding Ipamorelin's founding paper is still its most important one. In rat pituitary cells, anaesthetized rats and conscious pigs, it released GH about as powerfully as the older peptide GHRP-6 (pig ED50 of 2.3 nmol/kg versus 3.9 for GHRP-6), yet it did **not** raise ACTH or cortisol above baseline — even at doses more than 200 times its GH threshold [1]. That selectivity (releasing GH while leaving stress and milk hormones alone) is the single reason ipamorelin gets singled out from a crowded family of GH-releasing peptides. Dig deeper into the [Ipamorelin research](/research) for the mechanism, the human pharmacokinetics, and the studies behind each claim. Curious how the receptor part works? The [what does ipamorelin peptide do](/how-it-works) page walks the GHS-R1a pathway step by step. ## What the human data does — and does not — show Be precise where the data is precise, honest where it isn't. The human record is small. A pharmacokinetic study in eight healthy men per dose level pinned ipamorelin's terminal half-life at about 2 hours, with a single GH pulse peaking near 40 minutes after an IV dose [2]. That is solid, useful chemistry. The efficacy record is thinner. The only published Phase 2 trial gave 114 bowel-surgery patients 0.03 mg/kg IV twice daily and **missed** its primary endpoint — time to first tolerated meal was 25.3 hours on ipamorelin versus 32.6 on placebo, which was not statistically significant (p=0.15) [3]. No Phase 3 trial ever followed. So the marketing for anti-aging and fat loss runs well ahead of the controlled evidence, and the [ipamorelin benefits](/benefits) page keeps that line clearly drawn. ## Where this site stands This is an editorial research digest, not a clinic and not a store. We summarize the peer-reviewed literature on ipamorelin, lead with the newest findings, cite every quantitative claim, and never tell anyone to take anything. Ipamorelin is a research peptide with no approved human use — the word 'prescribed' in this domain is editorial framing about the gap between how the compound is talked about and what regulators have actually signed off on, which is nothing. Start with [the newest studies](/research), or skip to [what people report](/effects) if you want the honest, anecdote-labeled human angle first. --- New studies first, plain English always — an independent ipamorelin reading list, never a clinic, a prescription, or a store.